london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


The effectiveness of infliximab in controlling uveitis in Behçet's disease following vitrectomy operation

Poster Details

First Author: H.Khalil EGYPT

Co Author(s):    H. Raafat                  0   0 0   0 0   0 0   0 0

Abstract Details


to describe the effectiveness of infliximab in controlling ocular manifestations in Behҫet's Disease (BD) patients following vitrectomy operation


Cairo and BeniSweif University Hospitals


Twenty two male adult BD patients, diagnosed according to the International Study Group for Behcet's disease in1990 were included in the present study. All patients were candidates for vitrectomy due to their severe refractory posterior uveitis not responding to immunosuppressive drugs. The mean age of the patients was 30.6±5.16 years and mean disease duration was 6.3±3.1years. Full history taking, clinical examination and laboratory investigations performed to all patients. Disease activity was assessed using the Behcet's Disease Current Activity Form (BDCAF) score. Each patient underwent complete ophthalmologic examination, which included the best corrected visual acuity testing (VA), slit-lamp biomicroscopy, tonometry, and indirect ophthalmoscopy. Other investigations including fundus photography, fluorescein angiography, and ultrasonography were performed as indicated . infliximab was given in a dose of 5 mg/kg intravenous infusion over a three-hour period once every two weeks for 3 treatment sessions


Improvement of ocular manifestations were detected after Infliximab treatment regimen in 20 patients The mean VA of the patients improved (p=0.0113). ESR and dose of steroids significantly decreased following Infliximab treatment. (p= 0.0014 and 0.0001 respectively).


Infliximab treatment is effective in controlling ocular manifestations, following vitrectomy in BD patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy